Jingquan Jia, MD
Medical Oncology · Durham, NCNPI 1851739239
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,055 of the $2,995 with a category attached, or 68.6%. AstraZeneca accounts for 84.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $2,211 and has fallen 94.6% since, to $119 in 2025.
Across 12 payments — averaging $249.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Eisai Inc.$120
- Tempus AI, Inc$93
- Incyte Corporation$84
- Intera Oncology, Inc$53
- Beigene USA, Inc.$50
- plus $81 from 3 others
Across 17 payments — averaging $29,337 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$183K
- AstraZeneca$156K
- Amgen$104K
- Coherus Oncology, Inc.$56K
What the payments were for
- Consulting fees$2,05569%
- Speaking & faculty fees$2217%
- Food & beverage$71924%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $2,515 |
| Eisai Inc. | 1 | $120 |
| Tempus AI, Inc | 1 | $93 |
| Incyte Corporation | 1 | $84 |
| Intera Oncology, Inc | 1 | $53 |
| Beigene USA, Inc. | 1 | $50 |
| Karyopharm Therapeutics Inc. | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,995 in reported general payments places this provider in the 65th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $9,385 |
| Prochlorperazine Maleate | 36 | $657 |
| Ondansetron Hcl | 30 | $381 |
| Oxycodone Hcl | 21 | $293 |
| Pantoprazole Sodium | 16 | $190 |
| LoperamideLoperamide Hcl | 15 | $130 |
| Dexamethasone | 12 | $111 |
| Mirtazapine | 12 | $87 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Durham
- Thomas LeblancDurham$1.7M
- Andrew ArmstrongDurham$377K
- John StricklerDurham$319K
- Neal ReadyDurham$309K
- Michael HarrisonDurham$161K
- Jeffrey ClarkeDurham$140K
- Sundhar RamalingamDurham$93K
- Arif KamalDurham$50K
- Nelson ChaoDurham$45K
- Laura AlderDurham$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.